IDEXX Laboratories, Inc. (IDXX) EBITDA Margin: 34.13%
Is IDEXX Laboratories, Inc.’s EBITDA margin high or low?
IDEXX Laboratories, Inc.'s EBITDA margin of 34.13% is in line with its 5-year average of 31.99%, near the high end of its 5-year range (29.33%–34.13%).
The EBITDA margin for IDEXX Laboratories, Inc. (IDXX) is 34.13% as of Wednesday, June 10, 2026. It is above its 12-month average by 2.09% (33.43%).
IDXX EBITDA Margin Chart
IDXX Average EBITDA Margin Chart
IDXX Current vs Average EBITDA Margin Chart
IDXX EBITDA Margin Metrics
EBITDA MARGIN
34.13%
EBITDA MARGIN AVG TTM
33.43%
EBITDA MARGIN AVG 3Y
32.56%
EBITDA MARGIN AVG 5Y
31.99%
EBITDA MARGIN AVG 10Y
28.87%
EBITDA MARGIN AVG 15Y
27.06%
EBITDA MARGIN AVG 20Y
25.68%
CURRENT VS TTM AVG
+2.09%
CURRENT VS 3Y AVG
+4.81%
CURRENT VS 5Y AVG
+6.70%
CURRENT VS 10Y AVG
+18.22%
CURRENT VS 15Y AVG
+26.11%
CURRENT VS 20Y AVG
+32.92%
IDXX Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 34.13% | 33.43% | 32.56% | 31.99% |
| Humana Inc. (HUM) | $43.78B | 2.24% | 2.50% | 3.66% | 4.53% |
| Agilent Technologies, Inc. (A) | $37.17B | 26.41% | 27.60% | 26.98% | 26.47% |
| Zoetis Inc. (ZTS) | $34.20B | 42.98% | 42.41% | 42.38% | 41.76% |
| Centene Corporation (CNC) | $31.94B | -2.64% | 0.58% | 1.90% | 2.49% |
| Medline Inc. (MDLN) | $30.90B | 10.26% | 12.05% | 10.97% | 10.97% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 21.24% | 21.82% | 21.39% | 20.63% |
| DexCom, Inc. (DXCM) | $29.24B | 24.96% | 24.20% | 23.29% | 21.36% |
| Biogen Inc. (BIIB) | $29.00B | 31.60% | 31.28% | 30.38% | 32.54% |
| Veeva Systems Inc. (VEEV) | $26.73B | 28.68% | 27.64% | 24.37% | 25.68% |
Margin Comparison
Gross Margin
62.0%
EBITDA Margin
34.1%
Operating Margin
31.6%
Net Margin
24.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
IDEXX Laboratories, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The EBITDA margin for IDXX stock is 34.13%.
- Is IDEXX Laboratories, Inc.'s EBITDA margin high or low?
- IDEXX Laboratories, Inc.'s EBITDA margin of 34.13% is in line with its 5-year average of 31.99%, near the high end of its 5-year range (29.33%–34.13%).
- What is the TTM average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average EBITDA margin for IDXX stock is 33.43%.
- What is the 3Y average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average EBITDA margin for IDXX stock is 32.56%.
- What is the 5Y average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average EBITDA margin for IDXX stock is 31.99%.
- What is the 10Y average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average EBITDA margin for IDXX stock is 28.87%.
- What is the 15Y average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average EBITDA margin for IDXX stock is 27.06%.
- What is the 20Y average EBITDA margin for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average EBITDA margin for IDXX stock is 25.68%.
IDEXX Laboratories, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 34.13% |
| 2024-12-31 | 32.73% |
| 2023-12-31 | 33.26% |
| 2022-12-31 | 30.13% |
| 2021-12-31 | 32.34% |
| 2020-12-31 | 29.33% |
| 2019-12-31 | 26.74% |
| 2018-12-31 | 26.01% |
| 2017-12-31 | 25.47% |
| 2016-12-31 | 24.31% |
| 2015-12-31 | 23.12% |
| 2014-12-31 | 21.52% |
| 2013-12-31 | 23.41% |
| 2012-12-31 | 24.45% |
| 2011-12-31 | 23.37% |
| 2010-12-31 | 22.70% |
| 2009-12-31 | 21.93% |
| 2008-12-31 | 21.83% |
| 2007-12-31 | 19.22% |
| 2006-12-31 | 21.34% |
| 2005-12-31 | 21.89% |
| 2004-12-31 | 23.03% |
| 2003-12-31 | 16.89% |
| 2002-12-31 | 15.95% |
| 2001-12-31 | 20.41% |
| 2000-12-31 | 19.79% |
| 1999-12-31 | 17.97% |
| 1998-12-31 | 14.10% |
| 1997-12-31 | 3.80% |
| 1996-12-31 | 21.44% |
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky